Related Experiment Video
Updated: Sep 18, 2026
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Multiple sclerosis update
William T Mayr1, Moses Rodriguez
1Department of Neurology, Mayo Clinic Rochester, USA.
Abstract:
Multiple sclerosis (MS) is the most common cause of neurological disability in young European and North American adults. It is defined as dysfunction in different parts of the central nervous system at different points in time. The etiology is likely autoimmune, resulting from environmental and genetic factors. This article summarizes the symptoms, progression, diagnosis, and treatment of MS. MRI and CSF studies have been extremely helpful in identifying individual cases, but the diagnosis remains a clinical diagnosis, and one of exclusion. Methylprednisolone remains the preferred treatment for acute relapses, although plasma exchange has been shown to be helpful in cases when methylprednisolone has failed. Preventive immunomodulatory treatments are the focus of many current research efforts. Although these treatments have been shown to reduce the frequency of MS attacks, the reduction is modest, at 30%. The data that these drugs alter the progression of disability is less compelling.
Insights
Multiple sclerosis (MS) is a central nervous system autoimmune disease. Current treatments for acute relapses are effective, but disease-modifying therapies offer only modest benefits in reducing attacks and have less impact on disability progression.
Area of Science:
- Neurology
- Immunology
- Neuroimmunology
Background:
- Multiple sclerosis (MS) is a leading cause of neurological disability in young adults in Europe and North America.
- MS is characterized by dysfunction in the central nervous system over time, with likely autoimmune etiology involving genetic and environmental factors.
Purpose of the Study:
- To summarize the key aspects of multiple sclerosis, including its symptoms, disease progression, diagnostic methods, and current treatment strategies.
- To review the efficacy of treatments for acute relapses and the impact of disease-modifying therapies on MS course.
Main Methods:
- Review of existing literature on multiple sclerosis.
- Summary of diagnostic criteria and imaging techniques (MRI, CSF studies).
- Analysis of treatment outcomes for acute relapses and long-term management.
Main Results:
- Methylprednisolone is the primary treatment for acute MS relapses; plasma exchange is an alternative for refractory cases.
- Preventive immunomodulatory treatments reduce MS attack frequency by approximately 30%.
- Evidence for disease-modifying therapies altering disability progression in MS is less convincing.
Conclusions:
- MS diagnosis remains clinical, supported by MRI and CSF findings.
- While treatments for acute relapses are established, the long-term benefits of immunomodulatory therapies on disability progression require further investigation.
- Ongoing research focuses on improving preventive strategies for multiple sclerosis.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
01:22Myasthenia Gravis ll: Pathophysiology